4.8 Article

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

期刊

CANCER CELL
卷 16, 期 1, 页码 21-32

出版社

CELL PRESS
DOI: 10.1016/j.ccr.2009.04.012

关键词

-

资金

  1. Prostate Cancer Foundation
  2. Burroughs-Wellcome Fund
  3. Department of Defense [PC073284]
  4. American Society for Clinical Oncology
  5. Human Frontier Fellowship Organization
  6. National Human Genome Research Institute
  7. Susan Madden Fund
  8. Starr Cancer Consortium [1A-1 1]
  9. National Institutes of Health [T32CA09172-33, P50CA093459, R33CA128625, P01CA050661, P50CA112967, P30CA14051, R01CA085912, DP20DO02750-01]
  10. Novartis, Inc

向作者/读者索取更多资源

Dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway occurs frequently in human cancer. PTEN tumor suppressor or PIK3CA oncogene mutations both direct PI3K-dependent tumorigenesis largely through activation of the AKT/PKB kinase. However, here we show through phosphoprotein profiling and functional genomic studies that many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3. SGK3 undergoes PI3K- and PDK1-dependent activation in PIK3CA mutant cancer cells. Thus, PI3K may promote cancer through both AKT-dependent and AKT-independent mechanisms. Knowledge of differential PI3K/PDK1 signaling could inform rational therapeutics in cancers harboring PIK3CA mutations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据